<DOC>
	<DOCNO>NCT00101998</DOCNO>
	<brief_summary>A multicenter study evaluate effectiveness safety multiple dosage regimens investigational drug treatment constipation due prescription pain medication subject cancer pain . The study require five visit five-week period .</brief_summary>
	<brief_title>Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Alvimopan</mesh_term>
	<criteria>Inclusion criterion : Participant stage cancer minimum life expectancy least 3 month time Screening Visit . Participant take opioid therapy persistent cancer pain . Participant meet definition opioidinduced bowel dysfunction follow : Since start opioid therapy , subject decrease bowel movement ( BM ) frequency least one follow constipation symptom [ sensation incomplete evacuation , difficulty expel stool ( strain ) , hard stool ( abnormal stool consistency ) ] . Participant understand procedure , agree participate study , sign date informed consent form prior initiation studyrelated activity , include discontinuation prestudy laxative regimen prohibit medication . Participant able willing comply daily paper diary capable complete paper questionnaire study visit . Exclusion criterion : Participant pregnant lactating , plan become pregnant . Participant ambulatory . Participant participate another trial investigational drug ( unapproved ) , device procedure within 30 day Screening Visit . Participant unable eat , drink , take/hold oral medication . Participant take opioids management drug addiction . Participant unable unwilling discontinue use and/or refrain use laxative type formulation Screening Visit throughout entire study . Participant severe constipation appropriately manage subject immediate risk develop serious complication constipation . This would include subject report bowel movement 7 consecutive day prior Screening Visit . Participant gastrointestinal pelvic disorder know affect bowel transit , produce gastrointestinal ( GI ) obstruction , contribute bowel dysfunction . Participant currently take vinca alkyloids plan take vinca alkyloids study . Participant currently undergo abdominal radiation therapy and/or plan undergo abdominal radiation therapy study . Participant human immunodeficiency virus ( HIV ) infect , active hepatitis ( subtype include ongoing chronic hepatitis B ) , ever infect hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>OBD ( Induced Bowel Dysfunction )</keyword>
	<keyword>cancer pain</keyword>
	<keyword>pain medication</keyword>
	<keyword>constipation</keyword>
	<keyword>bowel</keyword>
	<keyword>bowel dysfunction</keyword>
</DOC>